The efficacy of second-line treatment for chronic myeloid leukemia (CML) plays an important role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase inhibitors (TKIs) are presently available: bosutinib, dasatinib, nilotinib, ponatinib. Each one has different safety and activity profiles, which are reviewed here. No controlled studies are available to guide treatment decision, which must be based on the characterization of leukemic cells, especially in cases of resistance to TKI, coupled with the safety profile of each TKI. Patient comorbidities also play an important role in the treatment decision, which can achieve a new durable response in over 50% of treated patients.(c) 2015 Wiley Periodicals, Inc.

GAMBACORTI PASSERINI, C., Aroldi, A., Cordani, N., Piazza, R. (2016). Chronic myeloid leukemia: Second-line drugs of choice. AMERICAN JOURNAL OF HEMATOLOGY, 91(1), 67-75 [10.1002/ajh.24247].

Chronic myeloid leukemia: Second-line drugs of choice

GAMBACORTI PASSERINI, CARLO
Primo
;
Aroldi, A;CORDANI, NICOLETTA
Penultimo
;
PIAZZA, ROCCO GIOVANNI
Ultimo
2016

Abstract

The efficacy of second-line treatment for chronic myeloid leukemia (CML) plays an important role in allowing CML patients to enjoy a normal life expectancy. Four tyrosine kinase inhibitors (TKIs) are presently available: bosutinib, dasatinib, nilotinib, ponatinib. Each one has different safety and activity profiles, which are reviewed here. No controlled studies are available to guide treatment decision, which must be based on the characterization of leukemic cells, especially in cases of resistance to TKI, coupled with the safety profile of each TKI. Patient comorbidities also play an important role in the treatment decision, which can achieve a new durable response in over 50% of treated patients.(c) 2015 Wiley Periodicals, Inc.
Articolo in rivista - Review Essay
CML; TKI; imatinib; second-line
English
67
75
9
GAMBACORTI PASSERINI, C., Aroldi, A., Cordani, N., Piazza, R. (2016). Chronic myeloid leukemia: Second-line drugs of choice. AMERICAN JOURNAL OF HEMATOLOGY, 91(1), 67-75 [10.1002/ajh.24247].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/95358
Citazioni
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
Social impact